Strides Exits Australia To ‘Double-Down’ On US Market
Executive Summary
Strides founder Arun Kumar says he’s succeeded in putting the company back on the road to health after it shocked financial markets by swinging to a quarterly loss last year. But as part of the recovery plan, the company is selling its key Australia generic business to “double-down” on the US market.
You may also be interested in...
Strides' US Revenues Soar As Recovery Strategy Is ‘Executing To Plan’
Strides Pharma is “very confident” about future after the Indian company’s fourth-quarter US revenues rocketed by 181% and EBITDA margins beat market expectations.
Strides' US Revenues Soar, Recovery Strategy ‘Executing To Plan’
Strides Pharma “very confident” about future after Indian generic company’s fourth-quarter US revenues rocketed 181% and EBITDA margins beat market expectations.
Strides plans for US growth
Earlier this year, Strides Pharma Science outlined plans to adopt a “recalibrated strategy” in the US, with a focus on launches through its own commercial front-end rather than through partners. As well as pledging to take up a “front-end bias” in the country, Strides had also said it would exit its partnership business and eschew new “partnership contracts” (Generics bulletin, 25 May 2018, page 5).